e-learning
resources
London 2016
Wednesday, 07.09.2016
Molecular immunology of the lung
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Katy Roach (Leicester, United Kingdom), Katy Roach, Chris Newby, Y. Amrani, Peter Bradding
Source:
International Congress 2016 – Molecular immunology of the lung
Session:
Molecular immunology of the lung
Session type:
Oral Presentation
Number:
4953
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Katy Roach (Leicester, United Kingdom), Katy Roach, Chris Newby, Y. Amrani, Peter Bradding. LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis. Eur Respir J 2016; 48: Suppl. 60, 4953
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Year: 2019
A novel chronic murine model of idiopathic pulmonary fibrosis
Source: International Congress 2018 – Pulmonary fibrosis: from models to patients
Year: 2018
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
KCa3.1 channel inhibition prevents fibrotic responses in a human lung explant model
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation
versus
fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 396s
Year: 2006
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
A longitudinal characterization of lymphangiogenesis in bleomycin-induced pulmonary fibrosis mouse model
Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation
Year: 2012
Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Antifibrosic effects of sulforaphane in human lung fibroblasts from idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2011
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
IGFBP-2 a new interesting target in IPF
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept